Focused Wealth Management’s Juniper Pharmaceuticals, Inc. Common Stock JNP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q3 | – | Sell |
-125
| Closed | -$1K | – | 748 |
|
|
2018
Q2 | $1K | Hold |
125
| – | – | ﹤0.01% | 634 |
|
|
2018
Q1 | $1K | Hold |
125
| – | – | ﹤0.01% | 681 |
|
|
2017
Q4 | $1K | Hold |
125
| – | – | ﹤0.01% | 666 |
|
|
2017
Q3 | $1K | Hold |
125
| – | – | ﹤0.01% | 635 |
|
|
2017
Q2 | $1K | Hold |
125
| – | – | ﹤0.01% | 689 |
|
|
2017
Q1 | $1K | Hold |
125
| – | – | ﹤0.01% | 673 |
|
|
2016
Q4 | $1K | Hold |
125
| – | – | ﹤0.01% | 675 |
|
|
2016
Q3 | $1K | Hold |
125
| – | – | ﹤0.01% | 651 |
|
|
2016
Q2 | $1K | Hold |
125
| – | – | ﹤0.01% | 651 |
|
|
2016
Q1 | $1K | Hold |
125
| – | – | ﹤0.01% | 633 |
|
|
2015
Q4 | $1K | Hold |
125
| – | – | ﹤0.01% | 660 |
|
|
2015
Q3 | $1K | Hold |
125
| – | – | ﹤0.01% | 662 |
|
|
2015
Q2 | $1K | Hold |
125
| – | – | ﹤0.01% | 643 |
|
|
2015
Q1 | $1K | Hold |
125
| – | – | ﹤0.01% | 657 |
|
|
2014
Q4 | $1K | Sell |
125
-80
| -39% | -$466 | ﹤0.01% | 640 |
|
|
2014
Q3 | $1K | Hold |
205
| – | – | ﹤0.01% | 668 |
|
|
2014
Q2 | $1K | Hold |
205
| – | – | ﹤0.01% | 649 |
|
|
2014
Q1 | $1K | Buy |
205
+80
| +64% | +$553 | ﹤0.01% | 612 |
|
|
2013
Q4 | $1K | Sell |
125
-2,550
| -95% | -$17.4K | ﹤0.01% | 606 |
|
|
2013
Q3 | $19K | Buy |
+2,675
| New | +$18K | 0.02% | 287 |
|
Focused Wealth Management's JNP Position: Q3 2018 in Review
Focused Wealth Management sold out of Juniper Pharmaceuticals, Inc. Common Stock (JNP) in Q3 2018, closing a stake of 125 shares — an estimated $1K sold.
Focused Wealth Management first reported a position in JNP in Q3 2013 and held it in 20 quarters. The position peaked at $19K in Q3 2013. 0 funds tracked by Wall St. Rank hold JNP as of Q3 2018.
- Focused Wealth Management reported no remaining Juniper Pharmaceuticals, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
- Focused Wealth Management sold 125 Juniper Pharmaceuticals, Inc. Common Stock shares in Q3 2018, an estimated $1K.
- Focused Wealth Management first reported a position in Juniper Pharmaceuticals, Inc. Common Stock in Q3 2013 and held it in 20 quarters.
- Focused Wealth Management's Juniper Pharmaceuticals, Inc. Common Stock position peaked at $19K in Q3 2013.
- 0 funds tracked by Wall St. Rank held Juniper Pharmaceuticals, Inc. Common Stock as of Q3 2018.
Based on Focused Wealth Management's 13F filing for Q3 2018, filed 13 Nov 2018.